Hepatitis C, Chronic: Clinical Trials

105 trials for Hepatitis C, Chronic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

88 completed, 11 terminated, 3 unknown, 3 withdrawn. 105 Phase 1, 26 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1105Completed 88, Terminated 11, Unknown 3, Withdrawn 3
Phase 226Completed 20, Terminated 4, Unknown 1, Withdrawn 1

Follow Hepatitis C, Chronic: new trials by email Literature Review of Hepatitis C, Chronic trials Research Report on Hepatitis C, Chronic

Trials (filtered) newest first · largest first

All 105 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects
AT-777, Placebo, AT-527 - Hepatitis C, Hepatitis C, Chronic
Phase 1 / Phase 2WithdrawnAtea Pharmaceuticals, Inc.2021-10-012022-06-08
The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
P1101 + Ribavirin - Hepatitis C, Chronic
Phase 1CompletedPharmaEssentia172020-11-262022-08-30
Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir
Sofosbuvir-Velpatasvir Drug Combination - Hepatitis C, Chronic
Phase 1CompletedCatherine Anne Chappell112020-10-222025-01-01
Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy Subjects
HEC74647, HEC110114 - Chronic Hepatitis C
Phase 1CompletedSunshine Lake Pharma Co., Ltd.282020-07-152020-11-05
The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects
HEC110114 Tablet, Sofosbuvir Tablet - Chronic Hepatitis C
Phase 1 / Phase 2CompletedSunshine Lake Pharma Co., Ltd.242020-07-062020-09-10
The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC74647 in HCV-infected Subjects
HEC74647PA capsule, placebo - Chronic Hepatitis C
Phase 1CompletedSunshine Lake Pharma Co., Ltd.282019-12-182020-03-19
The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects
HEC110114 tablet, Placebo Oral Tablet - Chronic Hepatitis C
Phase 1CompletedSunshine Lake Pharma Co., Ltd.932019-03-062020-03-18
Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy
Ledipasvir / Sofosbuvir Oral Product - Hepatitis C, Chronic, Hematologic Malignancy
Phase 1 / Phase 2CompletedAin Shams University242019-03-012023-08-22
The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects
HEC74647PA Capsule, placebo - Chronic Hepatitis c
Phase 1CompletedSunshine Lake Pharma Co., Ltd.1052018-09-042020-03-19
A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China
Ravidasvir 50mg, Ravidasvir 200mg - Chronic Hepatitis c
Phase 1CompletedAscletis Pharmaceuticals Co., Ltd.122018-01-152018-06-29
The Tolerability and Pharmacokinetics Study of Kangdaprevir Sodium Tablet in Healthy Adult Subjects
Kangdaprevir Sodium Tablet, placebo - Chronic Hepatitis c
Phase 1CompletedSunshine Lake Pharma Co., Ltd.1202018-01-112020-03-19
A Trial to Evaluate Safety, Tolerability, PK and Antiviral Activity of MB-110 in Hepatitis C Virus Infected Patients
MB-110, Placebo - Chronic Hepatitis C
Phase 1UnknownMicrobio Co Ltd402017-12-012017-04-05
Study of AT-527 in Healthy and HCV-Infected Subjects
AT-527, Placebo Comparator - Chronic Hepatitis C, Hepatitis C
Phase 1CompletedAtea Pharmaceuticals, Inc.882017-07-062020-02-18
A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)
Uprifosbuvir, Ruzasvir - Hepatitis C, Chronic
Phase 1CompletedMerck Sharp & Dohme LLC242016-01-222018-09-17
A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers
AL-335, ACH-3102, Simeprevir - Chronic Hepatitis C
Phase 1CompletedAlios Biopharma Inc.322015-07-312019-10-16
Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection
Autologous DC-vaccines - Hepatitis C, Chronic, Liver Diseases
Phase 1 / Phase 2CompletedRussian Academy of Medical Sciences102015-05-012019-05-10
First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
AL-335 matching placebo, AL-335 - Chronic Hepatitis C
Phase 1CompletedAlios Biopharma Inc.1122014-12-312019-10-16
The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects
yimitasvir, placebo - Chronic Hepatitis c
Phase 1CompletedSunshine Lake Pharma Co., Ltd.322014-12-032018-03-12
Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C
Chlorcyclizine HCl, Ribavirin - Chronic Hepatitis C
Phase 1 / Phase 2CompletedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)242014-03-202020-06-09
Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects
IDX21459, Matching Placebo - Chronic Hepatitis C
Phase 1TerminatedMerck Sharp & Dohme LLC482014-03-012016-01-26

Showing 20 of 105. Sign in to see all of them.

Narrower conditions

Hepatitis C (32)  ·  Liver Diseases (5)  ·  Hepatitis (3)  ·  Virus Diseases (3)  ·  Hepatitis, Viral, Human (2)  ·  Infections (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Flaviviridae Infections (1)  ·  HIV Infections (1)  ·  Hematologic Neoplasms (1)  ·  Hemophilia A (1)  ·  Leukemia (1)  ·  Recurrence (1)

Broader conditions

Blood-Borne Infections (105)  ·  Chronic Disease (105)  ·  Communicable Diseases (105)  ·  Digestive System Diseases (105)  ·  Disease Attributes (105)  ·  Hepatitis, Chronic (105)  ·  Pathologic Processes (105)  ·  Pathological Conditions, Signs and Symptoms (105)  ·  RNA Virus Infections (105)  ·  Flaviviridae Infections (104)  ·  Hepatitis, Viral, Human (103)  ·  Infections (103)  ·  Hepatitis (102)  ·  Virus Diseases (102)  ·  Liver Diseases (100)

Interventions

Ribavirin (14)  ·  Ritonavir (4)  ·  peginterferon alfa-2a (4)  ·  telaprevir (4)  ·  faldaprevir (3)  ·  peginterferon alfa-2b (3)  ·  samatasvir (3)  ·  AT-511 (2)  ·  BID protein, human (2)  ·  GSK2878175 (2)  ·  IDX184 (2)  ·  Simeprevir (2)  ·  Sofosbuvir (2)  ·  adafosbuvir (2)  ·  daclatasvir (2)

Sponsors

Merck Sharp & Dohme LLC (17)  ·  Boehringer Ingelheim (7)  ·  Sunshine Lake Pharma Co., Ltd. (7)  ·  Bristol-Myers Squibb (6)  ·  Hoffmann-La Roche (5)  ·  Alios Biopharma Inc. (4)  ·  Gilead Sciences (4)  ·  GlaxoSmithKline (3)  ·  Tanabe Pharma Corporation (3)  ·  Vertex Pharmaceuticals Incorporated (3)  ·  Atea Pharmaceuticals, Inc. (2)  ·  Bader, Ted, M.D. (2)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2)  ·  Presidio Pharmaceuticals, Inc. (2)  ·  Sandoz (2)

Countries

United States (38)  ·  China (8)  ·  France (8)  ·  Puerto Rico (8)  ·  Australia (5)  ·  Canada (5)  ·  Germany (5)  ·  New Zealand (5)  ·  Japan (3)  ·  Moldova (3)  ·  Belgium (2)  ·  Israel (2)  ·  Poland (2)  ·  South Korea (2)  ·  Spain (2)

Top investigators

Yanhua Ding, Doctor (5)  ·  Fumitaka Suzuki, MD (2)  ·  Nathaniel Brown, M.D. (2)  ·  Piyush Patel, M.D. (2)  ·  Alejandro Soza, MD (1)  ·  Aleksandra Pastrak, M.D. (1)  ·  Alexander A Ostanin, MD, PhD (1)  ·  Brian Sanderson (1)  ·  Carin MJ van Nieuwkerk, MD, PhD (1)  ·  Catherine Chappell, MD, MSc (1)

Results publications

PMID 20938912, PMID 20951424, PMID 21145839, PMID 21354234, PMID 21699798, PMID 22239508, PMID 22414766, PMID 22425702, PMID 23070151, PMID 23190247, PMID 23396509, PMID 23490393, PMID 23872824, PMID 23877706, PMID 24145880, PMID 24295986, PMID 24434503, PMID 24733462, PMID 25385099, PMID 25456558, PMID 25801562, PMID 26183611, PMID 26621580, PMID 26733671, PMID 27137491, PMID 27353271, PMID 29301580, PMID 29638206, PMID 29736243, PMID 30325939, PMID 30350297, PMID 30680407, PMID 31570394, PMID 31868916, PMID 32088322, PMID 34252301, PMID 34307188, PMID 37925363, PMID 39706761

NIH funding

2008 (2), 2009 (1), 2019 (1), R01DK090794 (1), R21AT003892 (1), R21HD101996 (1), R34HL109334 (1)